[{"bbox": [91, 98, 369, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [100, 168, 1548, 200], "category": "Section-header", "text": "# MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS"}, {"bbox": [91, 233, 1560, 394], "category": "Text", "text": "You should read the following discussion in conjunction with our restated financial statements attached in the chapter titled \"Financial Information of the Company\" beginning on page 179. You should also read the section titled \"Risk Factors\" on page 29 and the section titled \"Forward Looking Statements\" on page 18 of this Draft Red Herring Prospectus, which discusses a number of factors and contingencies that could affect our financial condition and results of operations. The following discussion relates to us, and, unless otherwise stated or the context requires otherwise, is based on our Restated Financial Statements."}, {"bbox": [91, 424, 1560, 618], "category": "Text", "text": "Our financial statements have been prepared in accordance with Indian GAAP, the Companies Act and the SEBI (ICDR) Regulations and restated as described in the report of our auditor dated September 24, 2025 which is included in this Draft Red Herring Prospectus under \"Financial Statements\". The Restated Financial Information has been prepared on a basis that differs in certain material respects from generally accepted accounting principles in other jurisdictions, including US GAAP and IFRS. Our financial year ends on March 31 of each year, and all references to a particular financial year are to the twelve-month period ended March 31 of that year."}, {"bbox": [91, 648, 393, 678], "category": "Section-header", "text": "## BUSINESS OVERVIEW"}, {"bbox": [91, 712, 1560, 937], "category": "Text", "text": "We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of Q-Line in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids)."}, {"bbox": [91, 967, 1560, 1127], "category": "Text", "text": "Our key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment's & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc."}, {"bbox": [91, 1159, 1186, 1193], "category": "Text", "text": "Our segment wise revenue for the last 3 fiscal years on Standalone basis has been present below: -"}, {"bbox": [91, 1220, 1558, 1456], "category": "Table", "text": "<table><thead><tr><th>Particulars</th><th>Amount FY 25</th><th>%</th><th>Amount FY 24</th><th>%</th><th>Amount FY 23</th><th>%</th></tr></thead><tbody><tr><td>Reagent</td><td>17,639.61</td><td>56.27%</td><td>13,579.63</td><td>66.68%</td><td>13,146.80</td><td>71.94%</td></tr><tr><td>Instrument</td><td>11,494.00</td><td>36.64%</td><td>5,669.69</td><td>27.84%</td><td>3,909.35</td><td>21.39%</td></tr><tr><td>Consumable/Spare</td><td>1,415.13</td><td>4.47%</td><td>607.83</td><td>2.98%</td><td>1,040.49</td><td>5.69%</td></tr><tr><td>Service</td><td>822.36</td><td>2.62%</td><td>507.47</td><td>2.49%</td><td>177.00</td><td>0.97%</td></tr><tr><td>Total</td><td>31,371.09</td><td>100.00%</td><td>20,364.61</td><td>100.00%</td><td>18,273.63</td><td>100.00%</td></tr></tbody></table>"}, {"bbox": [91, 1488, 1560, 1747], "category": "Text", "text": "We are research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. We leverage our R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for our certain Class of Reagent & equipment's and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, we undertake the manufacturing of these Reagent and equipment's and devices as per the technical collaboration and specifications provided by the partners or companies. With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2025, we employed 23 personnel at our R&D laboratories, which constituted 7.35% of our total permanent employee strength."}, {"bbox": [91, 1777, 1041, 1809], "category": "Text", "text": "Further, for the Make In India instruments, we are working on the following projects:"}, {"bbox": [91, 1811, 1560, 1908], "category": "List-item", "text": "* **Selectra Pro M**: We are currently manufacturing the Selectra Pro M—a medium-throughput, fully automatic clinical chemistry analyser—in India under a technical collaboration with one of the European companies. This instrument has been successfully scaled up for commercial production and is already serving laboratories across multiple regions."}, {"bbox": [91, 1908, 1560, 1974], "category": "List-item", "text": "* **Selectra Pro XL & Mircolab 300** - Building on our partnership with Elitech BV, we are developing \"Make in India\" prototypes of two additional analyzers:"}, {"bbox": [170, 1974, 1560, 2037], "category": "List-item", "text": "    1. **Selectra Pro XL** is a high-throughput, fully automatic clinical chemistry analyser designed for large laboratories and hospital networks."}, {"bbox": [170, 2037, 1517, 2069], "category": "List-item", "text": "    2. **Mircolab 300**, a semi-automatic clinical chemistry analyser tailored for smaller facilities and point-of-care settings."}, {"bbox": [91, 2100, 1501, 2133], "category": "Text", "text": "Both prototypes are in advanced stages of development and will undergo internal validation before moving to formal approval."}]